Literature DB >> 18268266

Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.

Virginie Demers1, Magda Melo, Cynthia Jackevicius, Jafna Cox, Dimitri Kalavrouziotis, Stéphane Rinfret, Karin H Humphries, Helen Johansen, Jack V Tu, Louise Pilote.   

Abstract

BACKGROUND: Reimbursement for outpatient prescription drugs is not mandated by the Canada Health Act or any other federal legislation. Provincial governments independently establish reimbursement plans. We sought to describe variations in publicly funded provincial drug plans across Canada and to examine the impact of this variation on patients' annual expenditures.
METHODS: We collected information, accurate to December 2006, about publicly funded prescription drug plans from all 10 Canadian provinces. Using clinical scenarios, we calculated the impact of provincial cost-sharing strategies on individual annual drug expenditures for 3 categories of patients with different levels of income and 2 levels of annual prescription burden ($260 and $1000).
RESULTS: We found that eligibility criteria and cost-sharing details of the publicly funded prescription drug plans differed markedly across Canada, as did the personal financial burden due to prescription drug costs. Seniors pay 35% or less of their prescription costs in 2 provinces, but elsewhere they may pay as much as 100%. With few exceptions, nonseniors pay more than 35% of their prescription costs in every province. Most social assistance recipients pay 35% or less of their prescription costs in 5 provinces and pay no costs in the other 5. In an example of a patient with congestive heart failure, his out-of-pocket costs for a prescription burden of $1283 varied between $74 and $1332 across the provinces.
INTERPRETATION: Considerable interprovincial variation in publicly funded prescription drug plans results in substantial variation in annual expenditures by Canadians with identical prescription burdens. A revised pharmaceutical strategy might reduce these major inequities.

Entities:  

Mesh:

Year:  2008        PMID: 18268266      PMCID: PMC2228358          DOI: 10.1503/cmaj.070587

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  13 in total

1.  A dog's breakfast: prescription drug coverage varies widely across Canada.

Authors:  A H Anis; D Guh
Journal:  Med Care       Date:  2001-04       Impact factor: 2.983

2.  Inter-provincial variation in government drug formularies.

Authors:  J P Grégoire; P MacNeil; K Skilton; J Moisan; D Menon; P Jacobs; E McKenzie; B Ferguson
Journal:  Can J Public Health       Date:  2001 Jul-Aug

Review 3.  Pharmaceutical policies in Canada. Issues and challenges.

Authors:  D E Angus; H M Karpetz
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 4.  Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.

Authors:  Joel Lexchin; Paul Grootendorst
Journal:  Int J Health Serv       Date:  2004       Impact factor: 1.663

5.  Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?

Authors:  Megan E Coombes; Steven G Morgan; Morris L Barer; Nino Pagliccia
Journal:  Healthc Q       Date:  2004

6.  Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit.

Authors:  Stephen B Soumerai; Marsha Pierre-Jacques; Fang Zhang; Dennis Ross-Degnan; Alyce S Adams; Jerry Gurwitz; Gerald Adler; Dana Gelb Safran
Journal:  Arch Intern Med       Date:  2006-09-25

7.  The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members.

Authors:  R E Johnson; M J Goodman; M C Hornbrook; M B Eldredge
Journal:  Health Serv Res       Date:  1997-04       Impact factor: 3.402

8.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

Authors:  R Tamblyn; R Laprise; J A Hanley; M Abrahamowicz; S Scott; N Mayo; J Hurley; R Grad; E Latimer; R Perreault; P McLeod; A Huang; P Larochelle; L Mallet
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

9.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.

Authors:  S B Soumerai; D Ross-Degnan; J Avorn; T j McLaughlin; I Choodnovskiy
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

10.  The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients.

Authors:  Louise Pilote; Christine Beck; Hugues Richard; Mark J Eisenberg
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

View more
  32 in total

1.  A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.

Authors:  John-Michael Gamble; Dean T Eurich; Jeffrey A Johnson
Journal:  Healthc Policy       Date:  2010-11

2.  Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.

Authors:  Jamie R Daw; Steven G Morgan
Journal:  Health Policy       Date:  2011-10-05       Impact factor: 2.980

3.  Leadership on prescription drugs needed.

Authors:  Edward Xie
Journal:  CMAJ       Date:  2012-07-10       Impact factor: 8.262

4.  Costs and benefits of free medications after myocardial infarction.

Authors:  Irfan A Dhalla; Monique A Smith; Niteesh K Choudhry; Avram E Denburg
Journal:  Healthc Policy       Date:  2009-11

5.  Development of a conceptual framework for understanding financial barriers to care among patients with cardiovascular-related chronic disease: a protocol for a qualitative (grounded theory) study.

Authors:  David J T Campbell; Braden J Manns; Brenda R Hemmelgarn; Claudia Sanmartin; Kathryn M King-Shier
Journal:  CMAJ Open       Date:  2016-06-08

6.  The power of "principles" in a national pharmaceuticals strategy.

Authors:  Catherine S Macpherson; Nuala P Kenny
Journal:  Healthc Policy       Date:  2009-02

7.  Addressing cost-related barriers to prescription drug use in Canada.

Authors:  Karen L Tang; William A Ghali; Braden J Manns
Journal:  CMAJ       Date:  2013-09-16       Impact factor: 8.262

8.  The born identity: prescription drug coverage by eligibility group.

Authors:  Fok-Han Leung; Rachael Frankford
Journal:  Can Fam Physician       Date:  2011-09       Impact factor: 3.275

9.  Estimated cost of universal public coverage of prescription drugs in Canada.

Authors:  Steven G Morgan; Michael Law; Jamie R Daw; Liza Abraham; Danielle Martin
Journal:  CMAJ       Date:  2015-03-16       Impact factor: 8.262

Review 10.  Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension.

Authors:  Scott W Klarenbach; Finlay A McAlister; Helen Johansen; Karen Tu; Maureen Hazel; Robin Walker; Kelly B Zarnke; Norman R C Campbell
Journal:  Can J Cardiol       Date:  2010-05       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.